Year: 2021

Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia

- Small Business Innovation Research (SBIR) contract to support development of pipeline program SENTI-202, a Logic Gated allogeneic CAR-NK cell...

Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company’s Phase 3 trial,...

error: Content is protected !!